Vident Investment Advisory’s BioCryst Pharmaceuticals BCRX Stock Holding History

Vident Investment Advisory’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-107,275	Closed	-$527K	–	896
2017 Q4	$527K	Buy	+107,275	New	+$520K	0.02%	544
2015 Q2	–	Sell	-131,891	Closed	-$1.19M	–	1067
2015 Q1	$1.19M	Buy	+131,891	New	+$1.37M	0.24%	105

Other funds holding BCRX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Vident Investment Advisory's BCRX Position: Q1 2018 in Review

Vident Investment Advisory sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2018, closing a stake of 107,275 shares — an estimated $527K sold.

Vident Investment Advisory first reported a position in BCRX in Q1 2015 and held it in 2 quarters. The position peaked at $1.19M in Q1 2015. 103 funds tracked by Wall St. Rank hold BCRX as of Q1 2018.

Vident Investment Advisory reported no remaining BioCryst Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
Vident Investment Advisory sold 107,275 BioCryst Pharmaceuticals shares in Q1 2018, an estimated $527K.
Vident Investment Advisory first reported a position in BioCryst Pharmaceuticals in Q1 2015 and held it in 2 quarters.
Vident Investment Advisory's BioCryst Pharmaceuticals position peaked at $1.19M in Q1 2015.
103 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2018.

Based on Vident Investment Advisory's 13F filing for Q1 2018, filed 14 May 2018.